参考文献/References:
[1]颜佳毅,张敏芳,倪兆慧,等.慢性肾脏病中晚期患者矿物质和骨代谢紊乱的知晓率、治疗率和控制率[J].中华肾脏病杂志,2012,28(1):10-15.[2]国家肾脏疾病临床医学研究中心.中国慢性肾脏病矿物质和骨异常诊治指南概要[J].肾脏病与透析肾移植杂志,2019,28(1):52-57.[3]Ketteler M,Block GA,Evenepoel P,et al.Executive summary of the 2017 KDIGO Chronic Kidney Disease Mineral and Bone Disorder(CKD-MBD)Guideline Update：what’s changed and why it matters[J].Kidney Int,2017,92(1):26-36.[4]Brennan MF,Doppman JL,Marx SJ,et al.Reoperative parathyroid surgery for persistent hyperparathyroidism[J].Surgery,1978,83(6):669-676.[5]Tominaga Y,Matsuoka S,Uno N.Surgical and medical treatment of secondary hyperparathyroidism in patients on continuous dialysis[J].World J Surg,2009,33(11):2335-2342.[6]王莉,李贵森,刘志红.中华医学会肾脏病学分会《慢性肾脏病矿物质和骨异常诊治指导》[J].肾脏病与透析肾移植杂志,2013,22(6):554-559.[7]Rudofsky G,Grafe IA,Metzner C,et al.Transient post-operative thyrotoxicosis after parathyroidectomy[J].Med Sci Monitor,2009,15(3):CS41-3.[8]孔令泉,邓世雄,任国胜,等.内分泌系统疾病[M]北京:人民卫生出版社,2017.[9]张自立,王金亮,徐辉,等.尿毒症规律血液透析患者继发性及三发性甲状旁腺功能亢进症合并甲状腺癌三例报告[J].天津医药,2017,45(5):522-525.